Injectable Drug Delivery conference 2018

SMi Group16 - 17 May 2018, London, UK.
The SMi Group are thrilled to present the launch of Injectable Drug Delivery Conference 2018. The event is taking place in central London on 16th and 17th May 2018, with two pre-conference workshops occurring on 15th May 2018.

The Global Injectable Drug Delivery Market is expected to reach $789.7 billion USD by 2024, with a compound annual growth rate (CAGR) of 11.5% during the period of 2017 to 2024, according to Research Markets Reports. Therefore, this conference will aim to discuss the key developments in this field and the latest technological advancements.

How Will You Benefit?

Network and learn from leading professionals such as:

Chairs for 2018:

  • Jean-René Authelin, Global Head, Pharmaceutical Engineering, Sanofi
  • Joel Richard, Senior Vice President, Peptides Development, Ipsen

Featured speakers:

  • Anand Subramony, Vice President, Novel Product Technologies, MedImmune
  • Mostafa Nakach, Head of Pharmaceutical Engineering, Sanofi
  • Maxime Gaillot, Senior Device Engineer, Roche
  • Pierre Goldbach, Senior Principal Scientist, Late-Stage Pharmaceutical and Processing Development, F. Hoffmann-La Roche AG
  • Fie Falck Larsen, Senior Usability Engineer, Injection Devices, Global Research and Development, LEO Pharma
  • Francesco Malavasi, Medical Device Quality Device Risk Manager, Novartis

Featured highlights:

  • Review device designs for a future portfolio
  • Explore risk management options for combination products
  • Hear how companies are tackling compatibility challenges of biologics with high volume injectors
  • Learn how vial-based novel delivery technologies can overcome complex dosing regiments
  • Discover how nanosystems can help address present and future challenges in injectable peptide delivery

View the full agenda online.

Early-Bird Rates

  • Book by 31st January and save £400
  • Book by 28th February and save £200
  • Book by 29th March and save £100

For further information and to register, please visit:
http://www.smi-online.co.uk/pharmaceuticals/uk/injectable-drug-delivery

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Sanofi and GSK sign agreements with the Government…

Sanofi and GSK have signed agreements with the Government of Canada for the supply of up to 72 million doses of an adjuvanted COVID-19 vaccine, beginning in 2021. Thom...

BioNTech and Pfizer initiate rolling submission to…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lea...

Johnson & Johnson initiates pivotal global Pha…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, J...

Scientists trace severe COVID-19 to faulty genes a…

More than 10 percent of young and healthy people who develop severe COVID-19 have misguided antibodies that attack not the virus, but the immune system itself, new resear...

Vir Biotechnology and GSK announce global expansio…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Eff...

Johnson & Johnson announces European Commissio…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Pur...

Johns Hopkins researchers publish COVID-19 'predic…

Using a combination of demographic and clinical data gathered from seven weeks of COVID-19 patient care early in the coronavirus pandemic, Johns Hopkins researchers today...

Web resources bring new insight into COVID-19

Researchers around the world are a step closer to a better understanding of the intricacies of COVID-19 thanks to two new web resources developed by investigators at Bayl...

COVID-19 vaccine AZD1222 clinical trial resumed in…

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). ...

COVID-19 Long-Acting AntiBody (LAAB) combination A…

AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside th...

Adequate levels of vitamin D reduces complications…

Hospitalized COVID-19 patients who were vitamin D sufficient, with a blood level of 25-hydroxyvitamin D of at least 30 ng/mL (a measure of vitamin D status), had a signif...

Protective antibodies persist for months in surviv…

People who survive serious COVID-19 infections have long-lasting immune responses against the virus, according to a new study led by researchers at Massachusetts General ...